NO328956B1 - Adenosinreseptorantagonist - Google Patents

Adenosinreseptorantagonist Download PDF

Info

Publication number: NO328956B1
Authority: NO; Norway
Prior art keywords: adenosine; compound; mmol; reference example; added
Prior art date: 1999-11-12

Application number

NO20022238A

Other languages

English (en)

Norwegian (no)

Other versions

NO20022238L (no

NO20022238D0 (no

Inventor

Carol L Ensinger

James E Dowling

Gnanasambandam Kumaravel

Russell C Petter

William F Kiesman

He Xi Chang

Ko Chung Lin

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2002-05-10

Publication date

2010-06-28

2002-05-10 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2002-05-10 Publication of NO20022238D0 publication Critical patent/NO20022238D0/no

2002-07-12 Publication of NO20022238L publication Critical patent/NO20022238L/no

2010-06-28 Publication of NO328956B1 publication Critical patent/NO328956B1/no

Links

239000000296 purinergic P1 receptor antagonist Substances 0.000 title description 8
229940121359 adenosine receptor antagonist Drugs 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 37
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
201000010099 disease Diseases 0.000 abstract description 9
239000002934 diuretic Substances 0.000 abstract description 9
230000001882 diuretic effect Effects 0.000 abstract description 6
210000003169 central nervous system Anatomy 0.000 abstract description 5
230000003412 degenerative effect Effects 0.000 abstract description 4
208000023504 respiratory system disease Diseases 0.000 abstract description 4
230000000747 cardiac effect Effects 0.000 abstract description 3
230000002265 prevention Effects 0.000 abstract description 3
108010060263 Adenosine A1 Receptor Proteins 0.000 abstract description 2
102000030814 Adenosine A1 receptor Human genes 0.000 abstract description 2
229940124639 Selective inhibitor Drugs 0.000 abstract description 2
230000003389 potentiating effect Effects 0.000 abstract description 2
239000002598 adenosine A1 receptor antagonist Substances 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 26
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
239000000203 mixture Substances 0.000 description 16
239000011541 reaction mixture Substances 0.000 description 14
239000002126 C01EB10 - Adenosine Substances 0.000 description 13
229960005305 adenosine Drugs 0.000 description 13
210000004027 cell Anatomy 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 11
239000005557 antagonist Substances 0.000 description 11
239000000872 buffer Substances 0.000 description 11
239000012528 membrane Substances 0.000 description 11
108050000203 Adenosine receptors Proteins 0.000 description 10
102000009346 Adenosine receptors Human genes 0.000 description 10
230000004913 activation Effects 0.000 description 10
230000027455 binding Effects 0.000 description 10
235000019439 ethyl acetate Nutrition 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000002287 radioligand Substances 0.000 description 8
239000007995 HEPES buffer Substances 0.000 description 7
241000700159 Rattus Species 0.000 description 7
210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
ULGKOBWVPCWKOE-UHFFFAOYSA-N 1-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC(C(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 ULGKOBWVPCWKOE-UHFFFAOYSA-N 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
UOSPNRSEBOMLKH-UHFFFAOYSA-N methyl 1-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 UOSPNRSEBOMLKH-UHFFFAOYSA-N 0.000 description 6
239000011734 sodium Substances 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
230000024924 glomerular filtration Effects 0.000 description 5
230000009871 nonspecific binding Effects 0.000 description 5
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 5
239000008188 pellet Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000007787 solid Substances 0.000 description 5
230000009870 specific binding Effects 0.000 description 5
VPQZQQILWCCMPS-UHFFFAOYSA-N 3-[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)-1-bicyclo[2.2.2]octanyl]prop-2-enoic acid Chemical compound C1CC(C=CC(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 VPQZQQILWCCMPS-UHFFFAOYSA-N 0.000 description 4
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
102000055025 Adenosine deaminases Human genes 0.000 description 4
206010007559 Cardiac failure congestive Diseases 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
208000030886 Traumatic Brain injury Diseases 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
238000010992 reflux Methods 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
206010003445 Ascites Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
210000002565 arteriole Anatomy 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000012267 brine Substances 0.000 description 3
229940030606 diuretics Drugs 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
239000010410 layer Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
230000009103 reabsorption Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000000126 substance Substances 0.000 description 3
ZFIIGRZPZQCDLJ-UHFFFAOYSA-N 1-(3-methoxy-3-oxopropyl)bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(CCC(=O)OC)CC2 ZFIIGRZPZQCDLJ-UHFFFAOYSA-N 0.000 description 2
SQUUDKCIIGURPO-UHFFFAOYSA-N 4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)bicyclo[2.2.2]octane-1-carbaldehyde Chemical compound C1CC(C=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 SQUUDKCIIGURPO-UHFFFAOYSA-N 0.000 description 2
VXNGWYZIFXWTDN-UHFFFAOYSA-N 8-[1-(hydroxymethyl)-4-bicyclo[2.2.2]octanyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound C1CC(CO)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 VXNGWYZIFXWTDN-UHFFFAOYSA-N 0.000 description 2
101150007969 ADORA1 gene Proteins 0.000 description 2
102000007471 Adenosine A2A receptor Human genes 0.000 description 2
108010085277 Adenosine A2A receptor Proteins 0.000 description 2
101150051188 Adora2a gene Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
241000270322 Lepidosauria Species 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
ZWTVVWUOTJRXKM-UHFFFAOYSA-N Tonapofylline Chemical compound C1CC(CCC(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 ZWTVVWUOTJRXKM-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
208000008784 apnea Diseases 0.000 description 2
RLNMGGVVNLNDIQ-UHFFFAOYSA-N benzyl 1-(3-methoxy-3-oxoprop-1-enyl)bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C=CC(=O)OC)(CC2)CCC12C(=O)OCC1=CC=CC=C1 RLNMGGVVNLNDIQ-UHFFFAOYSA-N 0.000 description 2
GWFIFOXXMPGWJZ-UHFFFAOYSA-N benzyl 1-(hydroxymethyl)bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(CO)(CC2)CCC12C(=O)OCC1=CC=CC=C1 GWFIFOXXMPGWJZ-UHFFFAOYSA-N 0.000 description 2
KWNJFSYQBINEBW-UHFFFAOYSA-N benzyl 1-formylbicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C=O)(CC2)CCC12C(=O)OCC1=CC=CC=C1 KWNJFSYQBINEBW-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
230000006864 diuretic response Effects 0.000 description 2
239000006196 drop Substances 0.000 description 2
206010013932 dyslexia Diseases 0.000 description 2
239000006274 endogenous ligand Substances 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000037406 food intake Effects 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
230000006609 metabolic stress Effects 0.000 description 2
LACGCRQWUHLNBA-UHFFFAOYSA-N methyl 3-(4-carbonochloridoyl-1-bicyclo[2.2.2]octanyl)propanoate Chemical compound C1CC2(C(Cl)=O)CCC1(CCC(=O)OC)CC2 LACGCRQWUHLNBA-UHFFFAOYSA-N 0.000 description 2
230000007971 neurological deficit Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000006461 physiological response Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000003653 radioligand binding assay Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000009529 traumatic brain injury Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
PQPNEOADNUUJFX-UHFFFAOYSA-N 1-(6-oxo-1,3-dipropyl-2-sulfanylidene-7h-purin-8-yl)bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC(C(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=S)CCC)=C2N1 PQPNEOADNUUJFX-UHFFFAOYSA-N 0.000 description 1
CPVMAYNPSFMOGK-UHFFFAOYSA-N 1-(hydroxymethyl)bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(CO)CC2 CPVMAYNPSFMOGK-UHFFFAOYSA-N 0.000 description 1
-1 2 x 10 ml) Chemical compound 0.000 description 1
ZSUSGBQRHRZDAP-UHFFFAOYSA-N 2,2-diethylbutan-1-amine Chemical compound CCC(CC)(CC)CN ZSUSGBQRHRZDAP-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
OSHOASUQHIDCOV-UHFFFAOYSA-N 5,6-diamino-1,3-dipropyl-2-sulfanylidenepyrimidin-4-one Chemical compound CCCN1C(N)=C(N)C(=O)N(CCC)C1=S OSHOASUQHIDCOV-UHFFFAOYSA-N 0.000 description 1
DWPGKJBUHDOVAD-UHFFFAOYSA-N 5,6-diamino-1,3-dipropylpyrimidine-2,4-dione;hydrochloride Chemical compound Cl.CCCN1C(N)=C(N)C(=O)N(CCC)C1=O DWPGKJBUHDOVAD-UHFFFAOYSA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241001123248 Arma Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
238000009020 BCA Protein Assay Kit Methods 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
239000012448 Lithium borohydride Substances 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000282341 Mustela putorius furo Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
241000009328 Perro Species 0.000 description 1
101100056293 Rattus norvegicus Akr7a2 gene Proteins 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000008649 adaptation response Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000002680 cardiopulmonary resuscitation Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000013058 crude material Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000011863 diuretic therapy Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000055905 human ADORA2A Human genes 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000007788 liquid Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
DTYOODQQYLGJQL-UHFFFAOYSA-N methyl 3-[4-[(4-amino-2,6-dioxo-1,3-dipropylpyrimidin-5-yl)carbamoyl]-1-bicyclo[2.2.2]octanyl]propanoate Chemical compound O=C1N(CCC)C(=O)N(CCC)C(N)=C1NC(=O)C1(CC2)CCC2(CCC(=O)OC)CC1 DTYOODQQYLGJQL-UHFFFAOYSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000023172 regulation of glomerular filtration Effects 0.000 description 1
230000007363 regulatory process Effects 0.000 description 1
230000008327 renal blood flow Effects 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000020874 response to hypoxia Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000000967 suction filtration Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20022238A 1999-11-12 2002-05-10 Adenosinreseptorantagonist NO328956B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16519199P	1999-11-12	1999-11-12
PCT/US2000/031058 WO2001034610A1 (en)	1999-11-12	2000-11-13	Polycycloalkylpurines as adenosine receptor antagonists

Publications (3)

Publication Number	Publication Date
NO20022238D0 NO20022238D0 (no)	2002-05-10
NO20022238L NO20022238L (no)	2002-07-12
NO328956B1 true NO328956B1 (no)	2010-06-28

Family

ID=22597852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022238A NO328956B1 (no)	1999-11-12	2002-05-10	Adenosinreseptorantagonist

Country Status (35)

Country	Link
US (5)	US6649600B1 (is)
EP (3)	EP1230243B1 (is)
JP (1)	JP2003513982A (is)
KR (2)	KR100863761B1 (is)
CN (2)	CN100390178C (is)
AT (1)	ATE424403T1 (is)
AU (1)	AU784556B2 (is)
BG (1)	BG65720B1 (is)
BR (1)	BR0015545A (is)
CA (1)	CA2390496A1 (is)
CY (1)	CY1110512T1 (is)
CZ (1)	CZ20021614A3 (is)
DE (1)	DE60041710D1 (is)
DK (1)	DK1230243T3 (is)
EA (1)	EA005211B1 (is)
EE (1)	EE05365B1 (is)
ES (1)	ES2323357T3 (is)
GE (1)	GEP20043303B (is)
HK (1)	HK1049155B (is)
IL (1)	IL149487A0 (is)
IS (1)	IS6379A (is)
ME (1)	MEP42208A (is)
MX (1)	MXPA02004796A (is)
NO (1)	NO328956B1 (is)
NZ (2)	NZ519426A (is)
PL (1)	PL206890B1 (is)
PT (1)	PT1230243E (is)
RS (1)	RS50381B (is)
SI (1)	SI1230243T1 (is)
SK (1)	SK287311B6 (is)
TR (1)	TR200201260T2 (is)
TW (1)	TWI272270B (is)
UA (1)	UA77391C2 (is)
WO (1)	WO2001034610A1 (is)
ZA (1)	ZA200203701B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL149486A0 (en) *	1999-11-12	2002-11-10	Biogen Inc	Purine derivatives and pharmaceutical compositions containing the same
EP1230243B1 (en) *	1999-11-12	2009-03-04	Biogen Idec MA Inc.	Poycyloalkylpurines as adenosine receptor antagonists
UA80258C2 (en) *	2001-09-06	2007-09-10	Biogen Inc	Methods of treating pulmonary disease
DE10145193C1 (de)	2001-09-13	2003-03-13	Sachtler Gmbh & Co Kg	Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten
CN1671716A (zh) *	2002-06-12	2005-09-21	拜奥根Idec马萨诸塞公司	用腺苷受体拮抗剂治疗缺血再灌注损伤的方法
EP1521584A1 (en)	2002-06-17	2005-04-13	Glaxo Group Limited	Purine derivatives as liver x receptor agonists
AU2003261206A1 (en) *	2002-07-19	2004-02-09	Aryx Therapeutics	Xanthine derivatives having adenosine a1-receptor antagonist properties
WO2004074247A2 (en)	2003-02-19	2004-09-02	Endacea, Inc.	A1 adenosine receptor antagonists
US20040229901A1 (en) *	2003-02-24	2004-11-18	Lauren Otsuki	Method of treatment of disease using an adenosine A1 receptor antagonist
RU2367442C2 (ru) *	2003-04-25	2009-09-20	Новокардия, Инк.	Способ нормализации мочеиспускания при нарушении функции почек
CA2528385C (en)	2003-06-06	2011-03-15	Endacea, Inc.	A1 adenosine receptor antogonists
CA2612338C (en)	2005-06-17	2015-02-03	Apogee Biotechnology Corporation	Sphingosine kinase inhibitors
WO2007059330A2 (en) *	2005-11-17	2007-05-24	Medkura Inc.	Cubane nucleoside analogs
AU2007235372A1 (en) *	2006-04-06	2007-10-18	Novacardia, Inc.	Co-administration of adenosine A1 receptor antagonists and anticonvulsants
CN101085785B (zh) *	2006-06-06	2011-09-21	中国科学院上海药物研究所	用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
JP2009540003A (ja) *	2006-06-16	2009-11-19	ノヴァカーディア，インク．	Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
EP2048944A4 (en) *	2006-07-17	2012-06-27	Tyratech Inc	COMPOSITIONS AND METHODS FOR CONTROLLING INSECTS
WO2008121882A1 (en) *	2007-03-29	2008-10-09	Novacardia, Inc.	Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) *	2007-03-29	2009-08-06	Howard Dittrich	Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
JP5603248B2 (ja) *	2007-12-21	2014-10-08	エンダセア，インコーポレイテッド	Ａ１アデノシン受容体アンタゴニスト
WO2009152458A1 (en) *	2008-06-13	2009-12-17	Biogen Idec Ma Inc.	Liquid formulation suitable for infusion comprising an adenosine receptor antagonist for treating heart failure and renal insufficiency.
WO2010011917A1 (en) *	2008-07-25	2010-01-28	Glaxosmithkline Llc	SEH AND 11β-HSD1 DUAL INHIBITORS
WO2011063268A2 (en)	2009-11-19	2011-05-26	Biogen Idec Ma Inc	Novel synthetic methods
CN102762625B (zh) *	2009-12-04	2014-06-18	联邦科学与工业研究组织	聚合材料
CN101709034B (zh) *	2009-12-14	2017-05-31	大连九信精细化工有限公司	双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
AR084457A1 (es) *	2010-12-22	2013-05-15	Lundbeck & Co As H	Derivados de biciclo[3,2,1]octilamida
AU2012275499A1 (en)	2011-06-27	2013-12-19	Kyorin Pharmaceutical Co., Ltd.	Bridged bicyclic compounds for the treatment of bacterial infections
US8962660B2 (en)	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators
US9598390B2 (en) *	2013-03-14	2017-03-21	Bristol-Myers Squibb Company	Bicyclo[2.2.2]acid GPR120 modulators
LT6401B (lt)	2015-07-28	2017-06-12	Vilniaus Universitetas	Karboanhidrazės selektyvūs inhibitoriai
EP3405183A4 (en)	2016-01-18	2019-12-11	Arisan Therapeutics Inc.	ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
WO2018075301A1 (en)	2016-10-19	2018-04-26	Eastman Chemical Company	Synthesis of bicyclo(2.2.2)octanes
WO2019018185A1 (en)	2017-07-15	2019-01-24	Arisan Therapeutics Inc.	ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
US11512067B2 (en)	2017-09-14	2022-11-29	Daiichi Sankyo Company, Limited	Compound having cyclic structure
US11518726B2 (en)	2017-10-11	2022-12-06	Eastman Chemical Company	Synthesis of bicyclo[2.2.2]octane derivatives
AR113820A1 (es)	2017-11-01	2020-06-17	Bristol Myers Squibb Co	Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
ES2941774T3 (es)	2018-09-18	2023-05-25	Bristol Myers Squibb Co	Acidos oxabiciclo como antagonistas de LPA
US10836899B2 (en)	2018-12-13	2020-11-17	Eastman Chemical Company	Polyesters with specified crystallization half-times

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0011399A1 (en)	1978-11-11	1980-05-28	FISONS plc	N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
DE8817122U1 (de)	1988-12-22	1993-02-04	Boehringer Ingelheim Kg, 55218 Ingelheim	Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) *	1989-09-01	1994-12-14	協和醗酵工業株式会社	キサンチン誘導体
US5290782A (en) *	1989-09-01	1994-03-01	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
ES2152207T3 (es)	1989-10-20	2001-02-01	Kyowa Hakko Kogyo Kk	Derivados condensados de la purina.
DE4019892A1 (de) *	1990-06-22	1992-01-02	Boehringer Ingelheim Kg	Neue xanthinderivate
JPH04270222A (ja) *	1991-02-25	1992-09-25	Kyowa Hakko Kogyo Co Ltd	脳機能改善剤
CA2061544A1 (en) *	1991-02-25	1992-08-26	Fumio Suzuki	Xanthine compounds
JPH0559056A (ja) *	1991-02-25	1993-03-09	Kyowa Hakko Kogyo Co Ltd	キサンチン誘導体
JPH04346986A (ja) *	1991-05-23	1992-12-02	Kyowa Hakko Kogyo Co Ltd	トリチウム標識化されたキサンチン誘導体
DE69229257D1 (de) *	1991-11-08	1999-07-01	Kyowa Hakko Kogyo Kk	Xanthinderivate zur Behandlung der Demenz
JP3115128B2 (ja) *	1991-11-08	2000-12-04	協和醗酵工業株式会社	キサンチン誘導体
US5336769A (en) *	1992-02-17	1994-08-09	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
US5342841A (en) *	1992-03-12	1994-08-30	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
JPH0616668A (ja) *	1992-03-12	1994-01-25	Kyowa Hakko Kogyo Co Ltd	キサンチン誘導体
TW252044B (is) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
US5384176A (en) *	1992-12-11	1995-01-24	Zimmerman; Richard C.	Phenolic acid sulfate esters for prevention of marine biofouling
WO1994016702A1 (fr) *	1993-01-26	1994-08-04	Kyowa Hakko Kogyo Co., Ltd.	Medicament contre l'elimination irreguliere des matieres fecales
JP3729874B2 (ja) *	1993-04-07	2005-12-21	協和醗酵工業株式会社	キサンチン誘導体
US5395836A (en)	1993-04-07	1995-03-07	Kyowa Hakko Kogyo Co., Ltd.	8-tricycloalkyl xanthine derivatives
US5446046A (en) *	1993-10-28	1995-08-29	University Of Florida Research Foundation	A1 adenosine receptor agonists and antagonists as diuretics
AU7675598A (en) *	1997-06-16	1999-01-04	Kyowa Hakko Kogyo Co. Ltd.	Hepatic edema remedy
AU7675498A (en) *	1997-06-16	1999-01-04	Kyowa Hakko Kogyo Co. Ltd.	Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) *	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU3757999A (en)	1998-04-24	1999-11-16	Biogen, Inc.	Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function
EP0955301A3 (en) *	1998-04-27	2001-04-18	Pfizer Products Inc.	7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
US6489331B1 (en)	1998-07-02	2002-12-03	Kyowa Hakko Kogyo Co., Ltd.	Remedies for diabetes
EP1230243B1 (en) *	1999-11-12	2009-03-04	Biogen Idec MA Inc.	Poycyloalkylpurines as adenosine receptor antagonists
IL149486A0 (en) *	1999-11-12	2002-11-10	Biogen Inc	Purine derivatives and pharmaceutical compositions containing the same
DE60304911D1 (de)	2002-02-25	2006-06-08	Eisai Co Ltd	Xanthin-Derivate als DPP-IV-Inhibitoren
AU2003261206A1 (en) *	2002-07-19	2004-02-09	Aryx Therapeutics	Xanthine derivatives having adenosine a1-receptor antagonist properties
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
WO2005077950A2 (en) *	2004-02-14	2005-08-25	Smithkline Beecham Corporation	Medicaments with hm74a receptor activity

2000
- 2000-11-13 EP EP00978546A patent/EP1230243B1/en not_active Expired - Lifetime
- 2000-11-13 SI SI200031029T patent/SI1230243T1/sl unknown
- 2000-11-13 JP JP2001537323A patent/JP2003513982A/ja active Pending
- 2000-11-13 HK HK02109310.2A patent/HK1049155B/en not_active IP Right Cessation
- 2000-11-13 PT PT00978546T patent/PT1230243E/pt unknown
- 2000-11-13 AT AT00978546T patent/ATE424403T1/de active
- 2000-11-13 IL IL14948700A patent/IL149487A0/xx not_active IP Right Cessation
- 2000-11-13 ME MEP-422/08A patent/MEP42208A/xx unknown
- 2000-11-13 RS YUP-338/02A patent/RS50381B/sr unknown
- 2000-11-13 BR BR0015545-4A patent/BR0015545A/pt not_active Application Discontinuation
- 2000-11-13 DK DK00978546T patent/DK1230243T3/da active
- 2000-11-13 EE EEP200200247A patent/EE05365B1/xx not_active IP Right Cessation
- 2000-11-13 US US09/711,543 patent/US6649600B1/en not_active Expired - Fee Related
- 2000-11-13 EA EA200200560A patent/EA005211B1/ru not_active IP Right Cessation
- 2000-11-13 PL PL356033A patent/PL206890B1/pl not_active IP Right Cessation
- 2000-11-13 EP EP09151275A patent/EP2070930A1/en not_active Withdrawn
- 2000-11-13 CN CNB008164398A patent/CN100390178C/zh not_active Expired - Fee Related
- 2000-11-13 CN CNA2008100921415A patent/CN101255162A/zh active Pending
- 2000-11-13 NZ NZ519426A patent/NZ519426A/en not_active IP Right Cessation
- 2000-11-13 MX MXPA02004796A patent/MXPA02004796A/es active IP Right Grant
- 2000-11-13 UA UA2002064822A patent/UA77391C2/uk unknown
- 2000-11-13 EP EP10183076A patent/EP2305684A1/en not_active Withdrawn
- 2000-11-13 KR KR1020027006093A patent/KR100863761B1/ko not_active Expired - Fee Related
- 2000-11-13 CA CA002390496A patent/CA2390496A1/en not_active Abandoned
- 2000-11-13 GE GE4819A patent/GEP20043303B/en unknown
- 2000-11-13 TR TR2002/01260T patent/TR200201260T2/xx unknown
- 2000-11-13 ES ES00978546T patent/ES2323357T3/es not_active Expired - Lifetime
- 2000-11-13 CZ CZ20021614A patent/CZ20021614A3/cs unknown
- 2000-11-13 KR KR1020087005528A patent/KR20080027971A/ko not_active Withdrawn
- 2000-11-13 NZ NZ527917A patent/NZ527917A/en not_active IP Right Cessation
- 2000-11-13 WO PCT/US2000/031058 patent/WO2001034610A1/en not_active Ceased
- 2000-11-13 AU AU16000/01A patent/AU784556B2/en not_active Ceased
- 2000-11-13 DE DE60041710T patent/DE60041710D1/de not_active Expired - Lifetime
- 2000-11-13 SK SK663-2002A patent/SK287311B6/sk not_active IP Right Cessation
- 2000-12-15 TW TW089123845A patent/TWI272270B/zh active
2002
- 2002-05-09 ZA ZA200203701A patent/ZA200203701B/xx unknown
- 2002-05-10 IS IS6379A patent/IS6379A/is unknown
- 2002-05-10 NO NO20022238A patent/NO328956B1/no not_active IP Right Cessation
- 2002-05-31 BG BG106762A patent/BG65720B1/bg unknown
2003
- 2003-08-21 US US10/646,454 patent/US20040067966A1/en not_active Abandoned
2006
- 2006-07-10 US US11/484,805 patent/US7579354B2/en not_active Expired - Fee Related
- 2006-07-13 US US11/487,764 patent/US20070015732A1/en not_active Abandoned
2009
- 2009-02-10 US US12/368,469 patent/US20090221821A1/en not_active Abandoned
- 2009-05-21 CY CY20091100543T patent/CY1110512T1/el unknown

Also Published As

Publication number	Publication date
CN1402729A (zh)	2003-03-12
UA77391C2 (en)	2006-12-15
PT1230243E (pt)	2009-06-12
EE05365B1 (et)	2010-12-15
NZ519426A (en)	2003-08-29
KR100863761B1 (ko)	2008-10-16
BG106762A (en)	2003-01-31
AU784556B2 (en)	2006-05-04
ATE424403T1 (de)	2009-03-15
AU1600001A (en)	2001-06-06
US20070015732A1 (en)	2007-01-18
CA2390496A1 (en)	2001-05-17
HK1049155B (en)	2009-11-06
IL149487A0 (en)	2002-11-10
JP2003513982A (ja)	2003-04-15
EP1230243A1 (en)	2002-08-14
GEP20043303B (en)	2004-01-12
BG65720B1 (bg)	2009-08-31
CZ20021614A3 (cs)	2002-07-17
ES2323357T3 (es)	2009-07-14
MEP42208A (en)	2011-02-10
US7579354B2 (en)	2009-08-25
TWI272270B (en)	2007-02-01
NO20022238L (no)	2002-07-12
EP2305684A1 (en)	2011-04-06
SI1230243T1 (sl)	2009-08-31
HK1049155A1 (en)	2003-05-02
DK1230243T3 (da)	2009-06-15
NO20022238D0 (no)	2002-05-10
US6649600B1 (en)	2003-11-18
US20090221821A1 (en)	2009-09-03
SK287311B6 (sk)	2010-06-07
PL356033A1 (en)	2004-06-14
CN101255162A (zh)	2008-09-03
MXPA02004796A (es)	2007-01-30
DE60041710D1 (de)	2009-04-16
EA200200560A1 (ru)	2002-10-31
BR0015545A (pt)	2002-08-06
RS50381B (sr)	2009-11-10
WO2001034610A1 (en)	2001-05-17
TR200201260T2 (tr)	2002-09-23
YU33802A (sh)	2006-01-16
KR20020049050A (ko)	2002-06-24
NZ527917A (en)	2005-03-24
US20060252730A1 (en)	2006-11-09
PL206890B1 (pl)	2010-10-29
EE200200247A (et)	2003-06-16
EP1230243B1 (en)	2009-03-04
IS6379A (is)	2002-05-10
EP2070930A1 (en)	2009-06-17
CY1110512T1 (el)	2015-04-29
SK6632002A3 (en)	2003-02-04
ZA200203701B (en)	2004-02-23
US20040067966A1 (en)	2004-04-08
CN100390178C (zh)	2008-05-28
KR20080027971A (ko)	2008-03-28
EA005211B1 (ru)	2004-12-30

Publication	Publication Date	Title
NO328956B1 (no)	2010-06-28	Adenosinreseptorantagonist
US20080004293A1 (en)	2008-01-03	Adenosine receptor antagonists and methods of making and using the same
JP2010053148A (ja)	2010-03-11	Ａ１アデノシンレセプターアンタゴニストとしての縮合プリン誘導体
JP2005515259A (ja)	2005-05-26	Ｅｄｇ受容体作動薬
AU2002219977A1 (en)	2002-08-15	Condensed purine derivatives as A1 adenosine receptor antagonists
JPH08506344A (ja)	1996-07-09	アデノシンモノホスフェートデアミナーゼの新規阻害剤
HK1059927B (en)	2009-04-24	Condensed purine derivatives as a1 adenosine receptor antagonists
AU2006200846A1 (en)	2006-03-23	Adenosine Receptor Antagonists and Methods of Making and Using the Same
HUP0203369A2 (hu)	2003-01-28	Adenozin receptor antagonista hatású policikloalkilpurinok, eljárás az előállításukra és alkalmazásuk

Legal Events

Date	Code	Title	Description
2012-06-25	MM1K	Lapsed by not paying the annual fees